Summary
The nephrotoxic effects of ifosfamide were assessed in 18 children and adolescents given cumulative doses of 32–112 g/m2 (1.6 g/m2 per day in sequential 5-day courses) with the uroprotectant mesna (1.2 g/m2 per day). Tubular nephrotoxicity was evaluated by measuring the urinary concentrations ofN-acetyl-β-d-glucosaminidase (NAG), alanine aminopeptidase (AAP), and total protein before and during sequential courses of therapy. Of 15 patients who had normal levels of tubular markers before ifosfamide therapy, only 1 developed a persistent increase in baseline values of the three tubular markers with the sixth course of ifosfamide. Although transient increases in the excretion of these markers were observed during each 5-day course of ifosfamide, the magnitude did not increase over sequential courses in these 15 patients. Of the remaining three patients who had increased NAG levels before ifosfamide therapy, two showed a progressive increase in enzymuria and proteinuria, and serum creatinine concentrations increased in a single patient who had obstructive uropathy. Our data suggest that children with normal renal function can be given large cumulative amounts of ifosfamide in fractionated doses with little risk of progressive clinical nephrotoxicity.
Similar content being viewed by others
References
Abeling N, Kraker J de, Gennip A van (1987) Abnormal plasma and urinary amino acid patterns in children on ifosfamide treatment (abstract). Proc Annu Meet Am Soc Clin Oncol 6: 48
Antman KH, Montella D, Rosenbaum C, Schwen M (1985) Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep 69: 499
Brock N, Pohl J (1983) The development of mesna for regional detoxification. Cancer Treat Rev 10 [Suppl A]: 33
Defronzo RA, Abeloff M, Braine H, Humphrey RL, David PJ (1974) Renal dysfunction after treatment with isophosphamide (NSC-109724). Cancer Chemother Rep 58: 375
Falkson G, Van Dyk JJ, Stapelberg R, Falkson HC (1982) Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment. Cancer Chemother Pharmacol 9: 81
Fossa SD, Talle K (1980) Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation. Cancer Treat Rep 64: 1103
Goren MP, Wright RK, Horowitz ME, Pratt CB (1987) Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna. Cancer Treat Rep 71: 127
Goren MP, Wright RK, Pratt CB, Horowitz ME, Dodge RK, Viar MJ, Kovnar EH (1987) Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by priorcis-diamminedichloroplatinum(II) therapy. Cancer Res 47: 1457
Hacke M, Schmoll HJ, Alt JM, Baumann K, Stolte H (1983) Nephrotoxicity ofcis-diamminedichloroplatinum with or without ifosfamide in cancer treatment. Clin Physiol Biochem 1: 17
Loehrer PJ Sr, Williams SD, Einhorn LH, Ansari R (1985) Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas. J Clin Oncol 3: 367
Moncreif M, Foot A (1989) Fanconi syndrome after ifosfamide. Cancer Chemother Pharmacol 23: 121
Patterson WP, Khojasteh A (1989) Ifosfamide-induced renal tubular defects. Cancer 63: 649
Pratt CB, Horowitz ME, Meyer WH, Etcubanas E, Thompson EI, Douglass EC, Wilimas JA, Hayes FA, Green AA (1987) Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep 71: 131
Sangster G, Kaye SB, Calman KC, Dalton JF (1981) Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity. Eur J Cancer Clin Oncol 20: 435
Stuart-Harris RC, Harper PG, Parsons CA, Kaye SB, Mooney CA, Gowing NF, Wiltshaw E (1983) High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 11: 69
Van Dyk JJ, Falkson HC, Van der Merwe AM, Falkson G (1972) Unexpected toxicity in patients treated with iphosphamide. Cancer Res 32: 921
Zalupski M, Baker LH (1988) Ifosfamide. J Natl Cancer Inst 80: 556
Author information
Authors and Affiliations
Additional information
Supported by Childhood Solid Tumor Program Projekt grant P01 CA 23099, Cancer Center Support (Core) grant CA-21765, and the American Lebanese Syrian Associated Charities (ALSAC)
Rights and permissions
About this article
Cite this article
Goren, M.P., Pratt, C.B. & Viar, M.J. Tubular nephrotoxicity during long-term ifosfamide and mesna therapy. Cancer Chemother. Pharmacol. 25, 70–72 (1989). https://doi.org/10.1007/BF00694342
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00694342